Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.

The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.

This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.

Read the article online: New England Journal of Medicine

Leave a Comment